# Science 37

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/science-37

- Industry: Healthcare IT
- Headquarters: Culver City, US
- Website: www.science37.com
- Total disclosed funding: $107M
- Latest round: Series D (Aug 20, 2020)
- Investors on record: 11

## About

Founded in 2014 Noah Craft and Belinda Tan, chaired by David Coman as CEO, and based in California, US, Science 37, Inc., provides universal access to clinical research enabling patients and providers to participate in accelerating the development of new treatments. In 2020, Science 37, Inc. raised USD 40.0 million in venture funding co-led by returning investors Lux Capital Management, Redmile Group, and PPD Investments, with participation from new and returning investors. In 2021, LifeSci Acquisition II Corp., a special purpose acquisition company (SPAC), combined with Science 37, Inc., valuing Science37 at USD 1.05 billion with a USD 200 million PIPE proceed. As of 2021, the company conducts over 95  decentralized clinical trials, engaging over 366,000 patients, and staffs over 500 employees. 

Founded in 2014 Noah Craft and Belinda Tan, chaired by David Coman as CEO, and based in California, US, Science 37, Inc., provides universal access to clinical research enabling patients and providers to participate in accelerating the development of new treatments. In 2020, Science 37, Inc. raised USD 40.0 million in venture funding co-led by returning investors Lux Capital Management, Redmile Group, and PPD Investments, with participation from new and returning investors. In 2021, LifeSci Acquisition II Corp., a special purpose acquisition company (SPAC), combined with Science 37, Inc., valuing Science37 at USD 1.05 billion with a USD 200 million PIPE proceed. As of 2021, the company conducts over 95  decentralized clinical trials, engaging over 366,000 patients, and staffs over 500 employees. 

Science37’s operating system is fully configurable allowing researchers to activate the patient engagement network or accessing the company’s network of telemedicine investigators. The company’s DCT OS supports any phase of study from pivot trials and RWE studies for a wide range of indications such as oncology, CNS, endocrinology, pediatrics, infectious, and rare diseases. Science37’s DCT OS™ offers mobile nurses, remote coordinators, patient communities, and connected devices.  

Post the merger between Science37 Inc and LifeSci Acquisition II Corp, the combined company will operate as Science37 and plans to list on the NASDAQ under the ticker symbol SNCE. The company plans on advancing its OS to further penetrate adjacent markets and power the future of clinical research.

## Funding rounds

- Series D, Aug 20, 2020, $40M — PPD Investments, Amgen Ventures, Lux Capital, GV, Glynn Capital, Sanofi Ventures, Redmile Group, Novartis, Mubadala Capital, LifeSci Partners
- Series C, Apr 25, 2017, $29M — Lux Capital, GV, Glynn Capital, Sanofi Ventures, Redmile Group, dRx Capital
- Series B, Oct 18, 2016, $31M — Lux Capital, Sanofi Ventures, Redmile Group, dRx Capital
- Series A, Oct 20, 2015, $6.5M — Lux Capital, dRx Capital

## Investors

- Lux Capital (https://capitalatlas.ai/funds/lux-capital) — Series A, Series B, Series C, Series D
- dRx Capital (https://capitalatlas.ai/funds/drx-capital) — Series A, Series B, Series C
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series B, Series C, Series D
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series B, Series C, Series D
- GV (https://capitalatlas.ai/funds/gv) — Series C, Series D
- Glynn Capital (https://capitalatlas.ai/funds/glynn-capital) — Series C, Series D
- PPD Investments (https://capitalatlas.ai/funds/ppd-investments) — Series D
- Amgen Ventures (https://capitalatlas.ai/funds/amgen-ventures) — Series D
- Novartis — Series D
- Mubadala Capital (https://capitalatlas.ai/funds/mubadala-capital) — Series D
- LifeSci Partners (https://capitalatlas.ai/funds/lifesci-partners) — Series D